Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Nektar Therapeutics
Headquarters: San Francisco, CA, United States of America
Website: http://www.nektar.com
Year Founded: 1990
Status: Public
Industry Sector: HealthTechnology
CEO: Howard W. Robin
Number Of Employees: N/A
Enterprise Value: $130,378,730
PE Ratio: -1.39
Exchange/Ticker 1: NASDAQ:NKTR
Exchange/Ticker 2: N/A
Latest Market Cap: $150,407,104
BioCentury | Dec 7, 2024
Data Byte
At $1B, PTC-Novartis deal ties record for cash up front
But partnership lands fourth on overall upfront payment
BioCentury | Apr 30, 2024
Deals
Deals Report: BMS-Repertoire to develop vaccines for autoimmunity
Plus: Regeneron, Mammoth to make CRISPR-based gene editing therapies, and updates from Vertex-TreeFrog, Ono-Deciphera and more
BioCentury | Jan 23, 2024
Management Tracks
Siga names Diem Nguyen CEO
Plus: Fish & Richardson names Sawert as principal and updates from ImmunoBrain and DiaMedica
BioCentury | Dec 7, 2023
Product Development
The first-in-human immuno-oncology problem
Companies face growing challenges in deciding whether to advance an immuno-oncology program based on early Phase I data
BioCentury | Nov 15, 2023
Deals
Alkermes oncology spinout Mural charts its future
Newly independent cancer biotech looks to twin 2025 readouts of IL-2 program that leads pipeline of engineered cytokine therapeutics
BioCentury | Aug 8, 2023
Deals
Aug. 7 Quick Takes: Eyeing cash, Ikena buys Pionyr
Plus: Astellas’ Zimura approved for geographic atrophy, Bavarian’s chikungunya vaccine heading to regulators and updates from Gracell, IO, Sage, Nektar and DotBio
BioCentury | Aug 4, 2023
Management Tracks
Karuna names new CFO and HR head
Plus: Freeman joins Zentalis as chief strategy officer, and updates from Complement,
BioCentury | Feb 24, 2023
Regulation
Feb. 23 Quick Takes: FDA approves Sanofi’s once-weekly hemophilia A therapy
Plus: CMS stays the course on Alzheimer's NCD and updates from Blueprint, Apellis, AZ, Nektar, Keymed, Prilenia and more
BioCentury | Feb 3, 2023
Management Tracks
Vessey to leave BMS in July
Plus: Nichols joining enGene as CEO and updates from Invivyd, Exai and more
BioCentury | Oct 28, 2022
Product Development
Oct. 28 Quick Takes: Gilead returns to $100B market cap on strong earnings
Plus: vaccines stand out for Sanofi, and updates from Outlook, PTC, Y-mAbs, Ascletis, Agios and more
Items per page:
1 - 10 of 532